Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,834 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo- C Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of a Pre-Workout Dietary Supplement

NCT02952014
View directory record Official record
Conditions
Dietary Modification
Interventions
C4 Extreme, C4 Extreme (without Advantra Z, Placebo
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 40 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 23, 2026, 6:09 PM EDT
Terminated Phase 1 Interventional

Randomized Study Of Exercise And Vitamin D In Frail Elderly Subjects

NCT00249704
View directory record Official record
Conditions
Elderly, Frail
Interventions
Vitamin D + Sham Exercise, Vitamin D Placebo + Exercise, Vitamin D Placebo + Sham Exercise, Vitamin D + Exercise
Drug · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
75 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Farmington, Connecticut • Hyattsville, Maryland • Roslindale, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2009 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

NCT03933488
View directory record Official record
Conditions
Healthy Participants
Interventions
TAK-994, TAK-994 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Glendale, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 23, 2026, 6:09 PM EDT
Recruiting Phase 3 Interventional

Cognitive Strategies in Early Psychosis 2

NCT07263022
View directory record Official record
Conditions
Psychosis, Schizophrenia Disorder, Schizoaffective Disorder, Major Depressive Disorder With Psychotic Features, Bipolar Disorder With Psychotic Features, Psychosis NOS, Schizophreniform Disorder, Psychotic Disorder, Cognition
Interventions
Modafinil, D-serine solution, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 35 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 1 Interventional

A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1

NCT01247194
View directory record Official record
Conditions
Chronic Genotype 1 Hepatitis C Virus Infection
Interventions
PPI-461, Placebo
Drug
Lead sponsor
Presidio Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 23, 2026, 6:09 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT07363694
View directory record Official record
Conditions
Moderate to Severe Chronic Obstructive Pulmonary Disease
Interventions
PF-07275315 dose 1, PF-07275315-dose 2, Placebo, PF-07275315-dose 3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 80 Years
Enrollment
1,156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
66
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of USP Methylene Blue on Cognitive and fMRI Brain Activity

NCT01836094
View directory record Official record
Conditions
Brain Activity
Interventions
Methylene Blue (USP grade, 280mg oral), Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 23, 2026, 6:09 PM EDT
Not listed Not applicable Interventional

Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies

NCT03682029
View directory record Official record
Conditions
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia-1, Cytopenia
Interventions
Vitamin C (ascorbic acid), Placebo
Dietary Supplement · Other
Lead sponsor
Copenhagen University Hospital, Rigshospitalet
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery

NCT02065245
View directory record Official record
Conditions
Frailty
Interventions
Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs), Placebo, Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
Biological
Lead sponsor
Longeveron Inc.
Industry
Eligibility
60 Years to 95 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Chiron Corp HCV E1/E2 Vaccine

NCT00500747
View directory record Official record
Conditions
Hepatitis C
Interventions
HCV E1E2/MF59, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 3 Interventional Results available

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

NCT01984424
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Atorvastatin, Placebo to Atorvastatin, Placebo to Ezetimibe, Ezetimibe, Placebo to Evolocumab, Evolocumab
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
18
States / cities
Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 23, 2026, 6:09 PM EDT
Terminated No phase listed Interventional Results available

Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17

NCT03462576
View directory record Official record
Conditions
Decompensated Cirrhosis
Interventions
Methacetin Breath Test, Emricasan, Placebo oral capsule
Combination Product · Drug
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lakewood Rch, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 3 Interventional Results available

Ibuprofen Sodium Tension Headache Study

NCT01362491
View directory record Official record
Conditions
Pain
Interventions
Ibuprofen Sodium, Standard Ibuprofen, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine

NCT03981952
View directory record Official record
Conditions
Risk Reduction
Interventions
Trivalent Invasive Salmonella Disease Vaccine (6.25 µg), Trivalent Invasive Salmonella Disease Vaccine (12 µg), Trivalent Invasive Salmonella Disease Vaccine (25 µg), Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C), Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Vitamin D on Lipids

NCT00723385
View directory record Official record
Conditions
Hypercholesterolemia, Vitamin D Deficiency
Interventions
Vitamin D (1000 or 2000 IU/day), Placebo
Dietary Supplement · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol

NCT01618916
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY3015014, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Honolulu, Hawaii • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists

NCT04183192
View directory record Official record
Conditions
Healthy Subjects, Pharmacokinetics, Pharmacodynamics
Interventions
Mepolizumab, Reslizumab, Placebo
Biological
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 2 Interventional

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

NCT01278134
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus placebo, RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
La Jolla, California • Sacramento, California • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 23, 2026, 6:09 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

NCT05327816
View directory record Official record
Conditions
Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention
Interventions
RSV preF-based Vaccine, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
11
States / cities
Long Beach, California • DeLand, Florida • Miami Lakes, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 23, 2026, 6:09 PM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream

NCT06334016
View directory record Official record
Conditions
Cannabis Dependence
Interventions
Biospecimen Collection, Cannabis sativa Extract, Nicotine, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years

NCT06573281
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Investigational RSV vaccine 1, Investigational RSV vaccine 2, Investigational RSV vaccine 3, Investigational RSV vaccine 4, Investigational RSV vaccine 5, Investigational RSV vaccine 6, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
5
States / cities
Rolling Hills Estates, California • Atlanta, Georgia • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 3 Interventional

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

NCT03847428
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Durvalumab, Bevacizumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 150 Years
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
34
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Early Phase 1 Interventional Results available

Treatment of HFpEF With Nitrate Supplement

NCT03289481
View directory record Official record
Conditions
Heart Failure With Normal Ejection Fraction
Interventions
Active lozenge, Placebo
Dietary Supplement · Drug
Lead sponsor
MaineHealth
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rockport, Maine
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 23, 2026, 6:09 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

NCT00457821
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor 25 mg/75 mg, Ivacaftor 75 mg/150 mg, Ivacaftor 150 mg or 250 mg, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 23, 2026, 6:09 PM EDT